Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Brepocitinib→

Brepocitinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1883299-62-4
Molecular formula
C18H21F2N7O
Molecular weight
389.4 g/mol
Drug class
Investigational dual Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) inhibitor
Mechanism of action
Inhibits JAK1 and TYK2, reducing signalling downstream of cytokine receptors that use these kinases. This is a pharmacological description of the investigational molecule; it should not be represented as a currently authorised therapy or a product-specific clinical mechanism unless a marketing authorisation is confirmed.
Indications / reported uses
  • Investigated for dermatomyositis and other immune-mediated inflammatory diseases. The catalogue entry is not assigned an authorised therapeutic indication without a current product label or marketing authorisation.

Sources: ClinicalTrials.gov — Brepocitinib and dermatomyositis · PubMed — Brepocitinib JAK1/TYK2 pharmacology · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Investigational dual Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) inhibitor

Mechanism of action

Inhibits JAK1 and TYK2, reducing signalling downstream of cytokine receptors that use these kinases. This is a pharmacological description of the investigational molecule; it should not be represented as a currently authorised therapy or a product-specific clinical mechanism unless a marketing authorisation is confirmed.

General use cases

  • Investigated for dermatomyositis and other immune-mediated inflammatory diseases. The catalogue entry is not assigned an authorised therapeutic indication without a current product label or marketing authorisation.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Brepocitinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Brepocitinib Permitted Daily Exposure (PDE) report (the Brepocitinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Brepocitinib Occupational Exposure Limit (OEL) report (the Brepocitinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.